Assistant Clinical Professor, Medicine (Hematology/Oncology), UCSF
| CONTACT | |
|
(415) 353-7070 (appts) Box 1710, UCSF; San Francisco, CA 94143-1710 |
additional websites: |
| EDUCATION | |
|
Duke University, B.S., Psychology / Neuroscience & Russian, 8/88-9/91
|
|
| PROFESSIONAL EXPERIENCE | |
|
7/03-Present |
Clinical Instructor in Medicine, UCSF Division of Hematology and Oncology |
|
8/05-present |
Assistant Clinical Professor, UCSF Division of Hematology and Oncology |
| HONORS & AWARDS | |
|
1991 |
Howard Hughes Undergraduate Research Grant |
|
1993 |
Graylyn Scholar |
|
1997 |
Alpha Omega Alpha Medical Honor Society |
|
1997 |
M. Robert Cooper Award for Excellence and Interest in Oncology |
|
2003 |
ASCO Merit Award Recipient |
|
2004 |
Breast Cancer Spore Career Development Award |
|
2006 |
UCSF General Clinical Research Center CreFF Award |
| SELECTED PUBLICATIONS | |
|
Melisko ME, Kunwar S, Prados M, Berger MS, Park JW. Brain metastases of breast cancer. Expert Reviews in Anticancer Therapy, Expert Rev Anticancer Ther. 2005 Apr;5(2):253-68. | |
|
Melisko ME, Hassein F, Metzroth L, Brown B, Patel K, Moore D, Rugo HS, and Tripathy D. Patient and Physician Attitudes Toward Breast Cancer Clinical Trials Ð Developing Interventions Based on Understanding Barriers, Clin Breast Cancer. 2005 Apr;6(1):45-54. | |
|
Melisko ME, Fox R, Venook A. Reactivation of Hepatitis C Virus after Chemotherapy for Colon Cancer. Clin Oncol (2004) 26: 204-205 | |
|
Edwards M, Hamolsky D, Melisko M, Hamel K, and Topp KS. Case Report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical Journal of Oncology Nursing, vol 9, no 2, April 2005: 189-193 | |
|
Park JW and Melisko ME. Resistance to Trastuzumab: Mechanistic Uncertainties. Clin Breast Cancer, vol 3, no 4, Oct 2002: 258-59 | |
|
Abstracts | |
|
Melisko ME, Scott J, McCormack RT, and Park JW. Use of circulating tumor cell detection assays in the CSF [abstract 1031]. Breast Canc Res Treat, 2006. | |
|
Melisko ME, Chew K, Baehner F, Moore D, Sneed PK, and Rugo HS. Clinical characteristics and molecular markers predicting the development and outcome of breast cancer brain metastases [abstr 1049]. Breast Canc Res Treat, 2005. | |
|
Tagliaferri M, Cohen I, Vogel C, Perez A, Tan-Chiu E, Franco S, Melisko M, Campbell M, Rugo H, Tripathy D. A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer [abstract 1079]. Breast Canc Res Treat, 2005. | |
|
Rugo HS, Dickler MN, Scott H, Moore DH, Melisko M, Yeh BM, Caravelli J, Brogi E, Hudis C, Park JW. Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation. Proc Am Soc Clin Oncol 23: page 10, 2005 (abstr 525) | |
|
Melisko ME, Peethambaram P, Rinn K, Jones LA, Sims RB, and Park JW. Immunotherapy targeting HER2/Neu: results from Phase 1 studies of APC8024 in women with metastatic breast cancer [abstract 6079]. Breast Canc Res Treat, 2004. | |
|
Melisko M, Sneed P, Moore D and Rugo H. Predicting survival in breast cancer patients with brain metastases. Proc Am Soc Clin Oncol 22: page 42, 2003 (abstr 168) | |
|
Melisko M, Hassein F, Metzroth L, Brown B, Patel K, Moore D, McMillan A, Rugo H, and Tripathy D. Patient and physician barriers to clinical trial participation: changes between 1997 and 2000 and attitudes towards complementary and alternative medicine [abstract 317]. Breast Canc Res Treat, 2002 | |
|
Park JW, Kenzer MC, Jones LA, Wollan J, Scott J, Rugo H, Shim V, Ewing C, Melisko M, Esserman LJ, Ashley E, Kylstra J. Autologous dendritic cells loaded with HER-2 derived antigen BA7072 (APC8024) stimulate specific immune responses in patients with metastatic breast cancer overexpressing HER2: a phase I/II study. San Antonio Breast Cancer Symposium, Dec 2002, abstr 22 and oral presentation |
|
|
2/1/07 |
|
